Study Published in Nature Digital Medicine Shows Potential of Machine Learning and Augmented Reality-based Digital Biomarkers in Alzheimer’s Detection
Today marks a historic day for all the scientists and researchers who have dedicated their lives to advancing our understanding of Alzheimer’s Disease over the last 20 years. For the more than 6 million individuals living with Alzheimer’s disease in the US, their families, and their caretakers, our team at Altoida celebrates the positive topline data reported on the CLARITY AD global Phase 3 clinical trial of Eisai and Biogen’s Lecanemab.
The theme of World Alzheimer’s Awareness Month, which is every September, is the power of knowledge. Many people think that Alzheimer’s disease is a normal part of aging, it isn’t. It is a progressive neurodegenerative disease that we believe can be slowed, stopped, and hopefully, prevented.
Lecanemab is an investigational therapy which acts as a disease-modifying agent and showed positive results in a large Phase 3 clinical trial. These results come after aducanumab became the first amyloid-clearing drug to win FDA approval. In this study on lecanemab, the rate of cognitive decline decreased by 27% for patients on therapy in a clinical trial as well as amyloid plaques.
As more disease-modifying agents come to market, innovation is needed to enable earlier detection and diagnosis of Alzheimer’s Disease and effective management of patients receiving therapy.
At Altoida, our team is developing the leading AI-driven digital diagnostics and management platform to accelerate and improve drug development, research, and care for patients with neurological diseases. Our innovative approach leverages immersive augmented reality (AR) and proprietary algorithms to evaluate the brain in a comprehensive, real-world mode of functioning and identify subtle cognitive changes. Our validated and evidence-based platform received FDA Breakthrough Device Designation in July 2021. We are continuing to advance Alzheimer’s research in collaboration with Eisai and Ionian University to gain new insights into the Alzheimer’s Disease continuum from various aspects of observational data.
Altoida is committed to advancing research and innovation for the early detection of Alzheimer’s Disease. We believe in health equity, access, and taking a precision approach to Alzheimer’s Disease that's driven by technology. The increasing integration of digital tools in healthcare will improve diagnosis, treatment, and management for everyone suffering from this debilitating neurological disease.
As we celebrate the success announced today, we must continue our efforts to discover new innovation and research to accelerate drug development in Alzheimer’s and all other dementias.
